Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A clinically validated diagnostic second-generation sequencing assay for detection of hereditary BRCA1 and BRCA2 mutations.

Bosdet IE, Docking TR, Butterfield YS, Mungall AJ, Zeng T, Coope RJ, Yorida E, Chow K, Bala M, Young SS, Hirst M, Birol I, Moore RA, Jones SJ, Marra MA, Holt R, Karsan A.

J Mol Diagn. 2013 Nov;15(6):796-809. doi: 10.1016/j.jmoldx.2013.07.004. Epub 2013 Oct 4. Erratum in: J Mol Diagn. 2014 May;16(3):378.

PMID:
24094589
2.

Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers.

Schrader KA, Masciari S, Boyd N, Salamanca C, Senz J, Saunders DN, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan PD, Olopade OI, Domchek SM, Ford J, Isaacs C, Brown P, Balmana J, Razzak AR, Miron P, Coffey K, Terry MB, John EM, Andrulis IL, Knight JA, O'Malley FP, Daly M, Bender P; kConFab, Moore R, Southey MC, Hopper JL, Garber JE, Huntsman DG.

J Med Genet. 2011 Jan;48(1):64-8. doi: 10.1136/jmg.2010.079814. Epub 2010 Oct 4.

3.

Mutation of FOXL2 in granulosa-cell tumors of the ovary.

Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG.

N Engl J Med. 2009 Jun 25;360(26):2719-29. doi: 10.1056/NEJMoa0902542. Epub 2009 Jun 10.

4.

Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients.

Wong MP, Cheang M, Yorida E, Coldman A, Gilks CB, Huntsman D, Berean K.

Pathology. 2008 Oct;40(6):611-6. doi: 10.1080/00313020802320614.

PMID:
18752129
5.

Tissue microarray analysis of connexin expression and its prognostic significance in human breast cancer.

Conklin C, Huntsman D, Yorida E, Makretsov N, Turbin D, Bechberger JF, Sin WC, Naus CC.

Cancer Lett. 2007 Oct 8;255(2):284-94. Epub 2007 Jun 20.

PMID:
17583422
6.

Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease.

Robinson AG, Turbin D, Thomson T, Yorida E, Ellard S, Bajdik C, Huntsman D, Gelmon K.

Clin Breast Cancer. 2006 Aug;7(3):254-61.

PMID:
16942643
7.

Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.

Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks CB, Dunn SE.

Cancer Res. 2006 May 1;66(9):4872-9.

8.

MDM2 protein expression is a negative prognostic marker in breast carcinoma.

Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB.

Mod Pathol. 2006 Jan;19(1):69-74.

9.

Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours.

Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE.

Breast Cancer Res. 2005;7(5):R796-807. Epub 2005 Aug 1.

10.

NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis.

Prentice LM, Shadeo A, Lestou VS, Miller MA, deLeeuw RJ, Makretsov N, Turbin D, Brown LA, Macpherson N, Yorida E, Cheang MC, Bentley J, Chia S, Nielsen TO, Gilks CB, Lam W, Huntsman DG.

Oncogene. 2005 Nov 10;24(49):7281-9.

PMID:
16027731
11.

Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.

Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE.

Oncogene. 2005 Jun 16;24(26):4281-92.

PMID:
15806160
12.

Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.

Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG.

Cancer. 2005 May 1;103(9):1770-7.

13.

P63 expression in lung carcinoma: a tissue microarray study of 408 cases.

Au NH, Gown AM, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL.

Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):240-7.

PMID:
15551738
14.

Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.

Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MC, Dunn SE, Hayes M, van de Rijn M, Bajdik C, Gilks CB.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6143-51.

15.

Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers.

Au NH, Cheang M, Huntsman DG, Yorida E, Coldman A, Elliott WM, Bebb G, Flint J, English J, Gilks CB, Grimes HL.

J Pathol. 2004 Sep;204(1):101-9.

PMID:
15307143

Supplemental Content

Loading ...
Support Center